• Anticholinergic Activity of "Bath Salt" Synthetic Cathinone Drugs of Abuse

      Clinton Canal; Rachel Lukavsky; Yiming Chen
      We conducted pharmacological, discovery-based research focused on a class of psychoactive drugs of abuse called synthetic cathinones, colloquially known as “bath salts.” This summer allowed me to learn new research techniques that are currently being used in drug discovery and development.
    • Exploring 5-HT2 Receptors as Targets for Treating Epilepsy in Fragile X Syndrome: A Preclinical Study of Fmr1 Knock-out Mice

      Tanishka Saraf; Yiming Chen; Jessica Armstrong; Clinton Canal
      This project explores the anticonvulsant potential of lorcaserin in Fragile X Syndrome in which epilepsy prevalence is ~25%. We did a full dose response (1-10 mg/kg) in an audiogenic seizure assay in Fmr1 knock-out mice. Lorcaserin did not affect prevalence at any dose but attenuated seizure severity to some extent.
    • Sex Differences in an Fmr1 Knock-out Mouse Model of Fragile X Syndrome

      Jessica Armstrong; Yiming Chen; Tanishka Saraf; Clinton Canal
      Possessing a single X-chromosome, fragile X syndrome (FXS) occurs more frequently in males than females, and FXS males typically have more severe clinical symptoms than FXS females. Genetic mosaicism (X-inactivation) in females with FXS is the presumed, exclusive reason for the lower symptom severity; we explored the hypothesis that other factors - sex hormones or sexually dimorphic brain systems - could be involved.